Korea Races For IPF Drug Development Amid Keen Global Interest
Following major global licensing out deals in the sector this year by South Korean bioventures Bridge Biotherapeutics and TiumBio, Scrip takes a look at why firms in the country are competitively pursuing development of drugs for IPF.
You may also be interested in...
Denali will collaborate with Sirion in Parkinson’s and Alzheimer’s diseases. Meanwhile, Lundbeck and Elevian unveil drug development partnerships with technology firms at the J.P. Morgan meeting.
Astellas inks agreement with Dyno Therapeutics for access to its CapsidMap platform for novel AAV vectors. Taiho takes option to Arcus TIGIT-targeted antibody candidates.
SK Biopharmaceuticals vice-president Haein Shin talks to Scrip about the company’s long journey to developing and launching novel innovative CNS drugs in global markets and what is behind its achievement, which is seen as unprecedented in the South Korean pharma industry.